Riskpilot← Back to searchSign inGet full accessAloop Therapeutics ApS
APSActiveCVR 43257498Sundkrogsgade 21Manufacture of pharmaceutical preparations · NACE 2120Est. 20226 employees
Revenue 2024
DKK -1,3M
-85% vs 2023
EBITDA margin
208.6%
+77% vs 2023
Equity ratio
99.7%
Financial strength
Net profit 2024
DKK -1,3M
+85% vs 2023
| Revenue | DKK -1,3M | -85% |
| EBITDA | DKK -2,8M | +77% |
| Net profit | DKK -1,3M | +85% |
| Total assets | DKK 30,8M | -10% |
| Equity | DKK 30,7M | -4% |
| Employees | 6 | — |
Legal name
Aloop Therapeutics ApS
CVR number
43257498
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
6. maj 2022
Share capital
DKK 300.000
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er forskning, udvikling og kommercialisering af lægemidler.
Address
Sundkrogsgade 21
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | -4.550 | -9.058 | -1.323 |
| Staff expenses | -816 | -2.846 | -1.437 |
| EBITDA | -5.366 | -11.904 | -2.760 |
| Depreciation & amort. | -0 | -0 | -0 |
| EBIT | -5.366 | -11.904 | -2.760 |
| Net financials | -22 | 380 | 857 |
| Profit before tax | -5.388 | -11.524 | -1.903 |
| Tax | -1.219 | -2.715 | -608 |
| Net profit | -4.169 | -8.809 | -1.295 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 13.442 | 34.250 | 30.814 |
| Equity | 10.831 | 32.022 | 30.727 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 2.611 | 2.228 | 87 |
| Total debt | 2.611 | 2.228 | 87 |
EBITDA margin
-276014100.0%
This company
15.8%
Market median
-1746924784% vs market
20222024
Equity ratio
99.7%
This company
38.2%
Market median
+161% vs market
20222024
Return on equity
-4.2%
This company
18.4%
Market median
-123% vs market
20222024
Net profit margin
-129515300.0%
This company
8.1%
Market median
-1598954421% vs market
20222024
Asset turnover
-0.04×
This company
1.12×
Market median
-104% vs market
20222024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RC Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (2) | ||
TK Management | Management | 2022 – 2024 |
SS Chief Executive Officer | Chief Executive Officer | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
| Board of Directors | 2022 – 2025 | |
| Chairman | 2022 – 2023 | |
| Chairman | 2023 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Aloop Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rodolphe Clerval | Chief Executive Officer | 0 companies |
| Thomas Kirkegaard Jensen | Management | 0 companies |
| Søren Sylvester Skjærbæk | Chief Executive Officer | 0 companies |
| Emmanuelle Coutanceau | Board of Directors | 0 companies |
| Jens Bo Rode Hansen | Chairman | 0 companies |
| Camilla Petrycer Hansen | Chairman | 0 companies |